Mydecine Innovations Group Inc. (MYCOF)
- Previous Close
0.0128 - Open
0.0086 - Bid --
- Ask --
- Day's Range
0.0086 - 0.0221 - 52 Week Range
0.0040 - 0.2930 - Volume
3,957 - Avg. Volume
10,619 - Market Cap (intraday)
1.161M - Beta (5Y Monthly) 3.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8800 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
www.mydecine.com3
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MYCOF
Performance Overview: MYCOF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYCOF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYCOF
Valuation Measures
Market Cap
577.28k
Enterprise Value
4.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.60
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-202.42%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-18.07M
Diluted EPS (ttm)
-0.8800
Balance Sheet and Cash Flow
Total Cash (mrq)
17.34k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.14M
Research Analysis: MYCOF
Company Insights: MYCOF
MYCOF does not have Company Insights